Nplate 500 micrograms powder and solvent for solution for injection

DRUG2 trials

Sponsors

Amgen Inc., Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Conditions

Chemotherapy-induced Thrombocytopenia in Adult Subjects with GastrointestinalPancreaticPrimary immune thrombocytopeniaor Colorectal Cancer

Phase 3

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Oxaliplatin-based Chemotherapy for Treatment of Gastrointestinal, Pancreatic, or Colorectal Cancer (RECITE)

CompletedCTIS2023-507148-35-00

Amgen Inc.Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, or Colorectal Cancer, Pancreatic

Start: 2019-10-03End: 2025-01-09Target: 60Updated: 2025-06-26

A multicentre, randomized, open-label study of romiplostim plus dexamethasone vs dexamethasone in patients with newly diagnosed primary immune thrombocytopenia

Active, not recruitingCTIS2024-514147-28-00

Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De SevillaPrimary immune thrombocytopenia

Start: 2022-12-02Target: 86Updated: 2025-12-12